Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 50, 85-92

Orchidectomy Enhances the Expression of endothelin-1 and ETB Receptors in Rat Portal Vein

Affiliations

Orchidectomy Enhances the Expression of endothelin-1 and ETB Receptors in Rat Portal Vein

Patrícia de S Rossignoli et al. J Smooth Muscle Res.

Abstract

Functional studies have shown that orchidectomy increases the effects of phenylephrine on rat portal veins, but that it is completely prevented in the presence of both ETA and ETB receptor antagonists. Although it suggests the involvement of endothelin-1 (ET-1), the local production of this vasoactive peptide has not been directly quantified in portal veins. Therefore, the aim of the present study was to verify if orchidectomy increases the local expression of ET-1 as well as ETA and ETB receptors in the rat portal vein. Indeed, the genic expression of ET-1, ETA and ETB receptors in rat portal veins taken from control (CONT), orchidectomized (ORX) and ORX plus testosterone-replacement therapy (ORX + T) animals were determined by Real Time RT-PCR. The results showed that orchidectomy induced a significant increment in genic expression of ET-1 and ETB receptors in the rat portal veins, which was completely reversed by testosterone replacement treatment. In conclusion, the results suggest that orchidectomy increases the production of ET-1 in the rat portal vein and that, at least partially, it may be related to the previously reported elevation of responses to phenylephrine.

Figures

Fig. 1.
Fig. 1.
Weight of seminal vesicles (A) and prostate gland (B) taken from control (CONT), orchidectomized (ORX) and ORX + testosterone-treated (ORX + T) animals. Data are the mean ± S.E.M. (n=10–12). ***P<0.001 related to the CONT; #P<0.001 related to the ORX + T (One-way ANOVA, followed by Bonferroni post-test).
Fig. 2.
Fig. 2.
Plasma testosterone levels (ng/dl) taken from control (CONT), orchidectomized (ORX) and ORX + testosterone-treated (ORX + T) animals. Data are the mean ± S.E.M. (n=10–12). ***P<0.001 related to the CONT; #P<0.001 related to the ORX + T (One-way ANOVA, followed by Bonferroni post-test).
Fig. 3.
Fig. 3.
Gene expression of endothelin-1 (ET-1) (A) as well as endothelin receptor subtypes ETB (B) and ETA (C), related to the GAPDH gene, detected in rat portal veins taken from control (CONT), orchidectomized (ORX) and ORX + testosterone-treated (ORX + T) animals. Data are the mean ± S.E.M. (n=6). *P<0.05 related to CONT (one way ANOVA followed by Bonferroni's post-test).

Similar articles

See all similar articles

Cited by 4 articles

References

    1. Lopes RAM, Neves KB, Carneiro FS, Tostes RC. Testosterone and vascular function in aging. Front Physiol. 2012; 3: 89. doi: 10.3389/fphys.2012.00089 - DOI - PMC - PubMed
    1. Bernini G, Versari D, Moretti A, Virdis A, Ghiadoni L, Bardini M, Taurino C, Canale D, Taddei S, Salvetti A. Vascular reactivity in congenital hypogonadal men before and after testosterone replacement therapy. J Clin Endocrinol Metab. 2006; 91(5): 1691–7. doi: 10.1210/jc.2005-1398 - DOI - PubMed
    1. Sader MA, Griffiths KA, Skilton MR, Wishart SM, Handelsman DJ, Celermajer DS. Physiological testosterone replacement and arterial endothelial function in men. Clin Endocrinol (Oxf). 2003; 59(1): 62–7. doi: 10.1046/j.1365-2265.2003.01796.x - DOI - PubMed
    1. Baum NH, Crespi CA. Testosterone replacement in elderly men. Geriatrics. 2007; 62(9): 15–8. - PubMed
    1. Seidman SN. Androgens and the aging male. Psychopharmacol Bull. 2007; 40(4): 205–18. - PubMed

Publication types

Feedback